The poly(ADP-ribose)polymerase (PADPRP) gene has been implicated in carcinogenesis through its role in DNA repair, replication and recombination. A two-allele polymorphism in the chromosome 13 PADPRP pseudogene has been studied in several racial groups. It has been suggested that the B allele, which results from a 193-bp deletion in the gene, predisposes to myeloma in Blacks. We assessed the association between chromosome 13 PADPRP pseudogene genotype, mutagen sensitivity (a marker reflecting host DNA repair capability), cigarette smoking, and lung cancer risk in a minority lung cancer case-control study. The chromosome 13 PADPRP pseudogene polymorphism was detected by polymerase chain reaction-based analysis. Mutagen sensitivity was measured by an in vitro assay that quantified bleomycin-induced chromatid breaks in peripheral blood lymphocyte cultures. We examined 121 cases (80 African-Americans and 41 Mexican-Americans) with previously untreated lung cancer and 171 matched controls. Our results suggested that the distribution of the PADPRP pseudogene genotype frequencies was significantly different among African-American and Mexican-American controls (P < 0.001). The susceptibility genotype (i.e. at least one B allele) was found in 82.5% of African-American cases, 79.4% of African-American controls, 53.7% of Mexican-American cases, and 32.4% of Mexican-American controls. The odds ratios (OR) and 95% confidence intervals for the PADPRP susceptibility genotypes were 2.3 (95% CI ⍧ 0.7-8.0) and 3.2 (95% CI ⍧ 1.0-10.3) for African-Americans and Mexican-Americans respectively, after adjustment by age, sex, pack-years and mutagen sensitivity. Patients with the susceptibility genotype appeared to have more mutagen-induced breaks than did patients with the other genotype. Only adenocarcinoma was significantly associated with the PADPRP susceptibility genotype (OR ⍧ 3.8). Mutagen sensitivity (ജ 1 break/cell) was significantly associated with lung cancer risk for both ethnic groups with increased ORs of above three-fold. On stratified analysis, synergistic interactions were noted for the PADPRP susceptibility genotype, mutagen sensitivity and smoking status. In Mexican-Americans, the ORs for PADPRP susceptibility genotype, mutagen sensitivity and both risk factors combined were 1.3, 2.7 and 17.1 respectively. The combined OR for the PADPRP susceptibility genotype and smoking status was 15.6. Therefore, this *Abbreviations: PADPRP, poly(ADP-ribose)polymerase; PCR, polymerase chain reaction; OR, odds ratio; CI, confidence interval.
Introduction
Poly(ADP-ribose)polymerase (PADPRP*) is a nuclear enzyme and DNA binding protein that catalyzes the ADP ribosylation of a variety of nuclear proteins and enzymes (1, 2) . The ADP ribosylation of these proteins is a direct response to DNAdamaging agents such as chemical carcinogens, and ultraviolet and ionizing radiation, which cause single-or double-stranded DNA breaks. Inhibition of the PADPRP prevents an increase in DNA ligase II activity (3) and drastically interferes with normal DNA repair (4) . PADPRP is also involved in integration of foreign DNA into host-cell DNA (5) . By modulating the structure and function of chromatin, PADPRP may also participate in the initiation of transcription and replication on the nuclear matrix (1) . Therefore, PADPRP has been linked with DNA repair, replication, recombination, gene expression and carcinogenesis.
Cherney et al. (6) have cloned the human PADPRP cDNA and mapped the active gene to human chromosome 1q42, and two PADPRP pseudogenes to 13q33-qter and 14. A two-allele PADPRP polymorphism, originally detected as a Hind-III restriction fragment length polymorphism (6) , has been studied in several racial groups (7, 8) . This polymorphism results from a 193-bp deletion of part of the PADPRP pseudogene at chromosome 13 (7) . A polymerase chain reaction (PCR) assay has been developed to analyze the polymorphism. Lyn et al. (7) reported an increase in the frequency of the B allele of the PADPRP-like gene on chromosome 13 in African-Americans with lung cancer. In another study, Cao et al. (8) found that the frequency of the B allele was higher in patients with multiple myeloma and monoclonal gammopathy than in controls without cancer. These results suggested that the PADPRPlike gene on chromosome 13 might be a disease-susceptibility locus. Because Lyn and colleagues studied only nine lung cancer patients, a larger study is warranted to evaluate the significance of their finding. It is known that there are marked racial differences in the incidence of lung cancer; for instance, African-Americans have the highest incidence and MexicanAmericans the lowest (9, 10) . Therefore, in this study, we examined the chromosome 13 PADPRP pseudogene in AfricanAmerican and Mexican-American lung cancer patients and controls. We also assessed the interactive effect between PADPRP genotype, bleomycin-induced mutagen sensitivity as a marker of DNA repair capability, and cigarette smoking on lung cancer risk.
Materials and methods

Study population
The data were derived from a hospital-based case control study of lung cancer in Houston, Galveston and San Antonio, Texas. The cases were 80 African-American and 41 Mexican-American men and women with newly diagnosed, previously untreated lung cancer identified by our collaborators at the University of Texas M. D. Anderson Cancer Center and various county, community and Veterans Administration hospitals in the Houston, Galveston, and San Antonio metropolitan areas. Ancestry was self-reported; Hispanics who were not of Mexican-American ancestry were not eligible for inclusion. There were no sex, histologic, age or stage restrictions. The controls were frequency-matched to the cases by age (Ϯ 5 years), sex, ethnicity (~2:1 for Mexican Americans and~1:1 for African Americans), and residence (Houston/ Galveston or San Antonio). The control group was a convenience sample accrued from community centers, churches, cancer-screening programs and employee groups. The participation rates were 86% for African-American cases and 85% for Mexican-American cases. The refusal reasons cited most commonly were that the patients were too ill or too distressed to be interviewed or reluctant to provide additional blood samples. We do not have refusal rates for controls because they volunteered by signing up on a list or showing up at a scheduled open recruitment event.
Data collection
Epidemiologic data were collected by personal interview. After informed consent was obtained, a structured interview lasting~45 min was conducted by trained bilingual interviewers. Data were collected on sociodemographic characteristics, recent and prior tobacco use, and other lifestyle habits. At the completion of the interview, blood was drawn into heparinized tubes for cytogenetic and molecular genetic analyses.
Polymorphism analysis
After we isolated DNA from the subjects' peripheral lymphocytes with standard techniques, we used the technique of Lyn et al. (7) to amplify the deleted area in the chromosome 13 PADPRP pseudogene (containing bases 636-1230 of the Hind-III clone of the chromosome 13 PADPRP pseudogene) to amplify the genomic DNA (7). The following primers were used: 5Ј-AAG AAG CCA ACA TCT GAG CT-3Ј and 5Ј-TTT CCT TGT CAT CCT TCA GC-3Ј. These primers have mismatches at their 3Ј ends and internal mismatches that prevent amplification of related PADPRP sequences on chromosomes 1 and 14. PCR was performed in 25-µl reaction mixtures containing 1.5 mM MgCl 2 , 0.2 mM dNTPs, 1 µM primers, 1 µg of template DNA, 1.5 U of Taq polymerase, and PCR buffer (20 mM Tris-HCl, pH 8.4; 50 mM KCl, Boehringer Mannheim, Indianapolis, IN). After an initial denaturation at 94°C for 4 min, the DNA was amplified by 10 cycles of 45 s at 94°C, 60 s at 60°C and 90 s at 72°C; followed by 25 cycles of 30 s at 94°C, 40 s at 62°C and 60 s at 72°C, and a final extension step of 72°C for 5 min. The PCR products were then resolved on a 2.1% agarose gel (at 5 V/cm) containing ethidium bromide. The PADPRP A allele fragment was 595 bp, and the B allele was 402 bp.
Mutagen sensitivity assay
This assay has been described in detail previously (11) . Briefly, peripheral lymphocyte cultures were established as follows: 1 ml of whole blood was added to 9 ml of RPMI 1640 supplemented with 20% fetal bovine serum, 2 mM L-glutamine, 50 U/ml penicillin, 100 µg/ml streptomycin and 1.3% phytohemagglutinin. After 3 days of incubation, the cultures were treated with bleomycin (0.03 U/ml) for 5 h. During the last hour, the cells were treated with colcemid (0.04 µg/ml) to arrest the cells in mitosis before harvesting for conventional air-dried preparations. All prepared slides were coded and stained with Giemsa without banding. The number of breaks in 50 metaphases per sample was counted and expressed as the average number of breaks per cell. Only frank chromatid breaks or exchanges were recorded; chromatid gaps or attenuated regions were disregarded. The slides were coded and read without knowledge of the subjects' case or control status.
Statistical analysis
For smoking status, a person who had smoked at least 100 cigarettes in his or her lifetime was regarded as a smoker. A former smoker was defined as one who had smoked cigarettes in the past but had stopped smoking at least 1 year before diagnosis (or 1 year before the study began, for the controls). Cumulative cigarette dose (pack-years) was calculated by the following formula: pack-years ϭ [(number of cigarettes smoked per day)ϫ(years smoked)] / 20 cigarettes. Lighter and heavier smokers were categorized by the 75th percentile pack-year value among controls, which was 28 pack-years and was also approximately the 25th percentile pack-year for the cases. Mutagen sensitivity was dichotomized at the level of 1 break/cell. Pearson's χ 2 test or Fisher's exact test (when the expected number in any cell was Ͻ5) was used to compare the distribution of the PADPRP pseudogene genotypes between cases and controls and among various histopathological types. All analyses were stratified by ethnicity. When the sample size was small, exact methods were applied for estimating and testing odds ratio (OR) using StatXact (12) . Hardy-Weinberg equilibrium was tested by a goodness-of-fit χ 2 test to compare the observed genotype frequencies within MexicanAmerican and African-American case and control groups to the expected genotype frequencies calculated from the observed allele frequencies. Stratified analysis was used to test for the interactions between PADPRP genotype, mutagen sensitivity, and smoking status or pack-years smoked. Logistic regression was conducted to estimate risks, which were adjusted for multiple factors by using STATA statistical software (13) .
Results
In this study, we examined 121 lung cancer patients and 171 controls (80 African-American and 41 Mexican-American cases and 97 African-American and 74 Mexican-American controls). Table I summarizes the distribution of select variables for the cases and controls by ethnicity. Women were overrepresented in the control group (38.1% versus 28.7% among the African-Americans and 33.8% versus 22.0% among the Mexican-Americans), but the differences were not statistically significant. There were no significant differences between cases and controls in terms of mean age for both ethnic groups. Predictably, the cases were significantly more likely to have ever smoked (96.2% versus 61.9% for African-Americans and 87.8% versus 46.0% for Mexican-Americans), to have smoked more cigarettes per day (25. The frequency distribution of the three genotypes by ethnic group and case-control status is presented in Table II . It is notable that genotype distribution was strongly associated with ethnicity. Significantly more African-American controls than Mexican-American controls had at least one B allele (79.4% versus 32.4%) (P Ͻ 0.001). When the AB and BB genotypes were combined and compared with the AA genotype, the AB and BB genotypes were significantly more common in patients than in the controls for Mexican-Americans (P ϭ 0.026); however, there was no significant difference for AfricanAmericans. The frequencies of the A and B alleles in controls were 0.402 and 0.598 for African-Americans and 0.804 and 0.196 for Mexican Americans and the patients had values of 0.406 and 0.594 versus 0.683 and 0.317 respectively. On the allelic analysis, the ORs for the B allele were 1.0 (95% CI ϭ 0.8-1.2) for African-Americans and 1.9 (95% CI ϭ 1.6-2.3) for Mexican-Americans. The genotypes were in HardyWeinberg equilibrium.
The univariate and covariate adjusted ethnic-specific risk estimates for mutagen sensitivity versus non-sensitivity and PADPRP pseudogene susceptibility genotype (i.e. at least one B allele) compared with the AA genotype are summarized in Table III . Among the African-Americans, 54.6% of the lung cancer cases were mutagen sensitive (defined as having ജ1.0 breaks/cell) compared with 28.4% of the control subjects, and 61.3% of the Mexican-American lung cancer cases were mutagen sensitive compared with 23.3% of their controls. The ORs for mutagen sensitivity obtained by multivariate analyses (adjusted for age, sex, ethnicity, pack-years and genotype) were 3.2 (95% CI ϭ 1.2-8.4) and 3.6 (95% CI ϭ 1.1-11.2) for African-Americans and Mexican-Americans respectively (Table III) . The PADPRP pseudogene genotype results are reported using the combined genotypes AB and BB as the susceptible genotype, because no marked differences were noted when the two types were analyzed separately. The overall lung cancer risk for individuals who had the PADPRP pseudogene susceptibility genotype was significantly elevated for Mexican-Americans (OR ϭ 3.2, 95% CI ϭ 1.0-10.3), For African-Americans, the risk was increased but not statistically significant (OR ϭ 2.3, 95% CI ϭ 0.7-8.0). When lung cancer We also found a significant association between the B allele and DNA breaks in Mexican-Americans. The mean of mutageninduced breaks per cell increased significantly in MexicanAmerican lung cancer patients as the number of B alleles increased. The mean breaks/cell was 1.1, 1.2 and 2.0 for patients with the AA, AB and BB genotypes respectively. However, only 14, 14 and three subjects were present in the respective genotype group.
We also performed stratified analysis to examine the interactions between PADPRP pseudogene genotype and both cigarette smoking and mutagen sensitivity (Table IV) . The reference group were subjects with the AA genotype who had never smoked or were not mutagen sensitive. In MexicanAmericans, the OR for having the susceptibility genotype was 1.3 (95% CI ϭ 0.3-5.8); for being mutagen sensitive alone, the OR was 2.7 (95% CI ϭ 0.6-11.4). For individuals who were mutagen sensitive and had the susceptibility genotype, the OR was 17.1 (95% CI ϭ 3.2-112.0). This large combined OR suggests that the joint effect was greater than multiplicative. However, in the logistic model, the interaction term was not statistically significant, probably due to the small sample size, which also produced the wide CI. The multiplicative interaction between having ever smoked and the PADPRP susceptibility genotype was strong in Mexican-Americans, whose ORs for the PADPRP susceptibility genotype, ever smoker and both risk factors combined were 1.6 (95% CI ϭ 0.1-15.3), 6.8 (95% CI ϭ 1.6-39.8) and 15.6 (95% CI ϭ 3.5-92.3) respectively. We next dichotomized the subjects by smoking status into two pack-year categories (ജ0.1 and Ͻ28 and ജ28 pack-years, based on the distribution of smoking history in the overall group after excluding non-smokers). The effects of the PADPRP susceptibility genotype and pack-years of smoking followed the same pattern, with a markedly increased risk in the heaviest smokers. Because of the small sample size, the interaction 96 pattern between PADPRP genotype and cigarette smoking was hard to measure for African-Americans (Table V) . However, the interaction between mutagen sensitivity and PADPRP susceptibility genotype was not evident for African-Americans. The small sample size prevented us from analyzing three-way interactions among PADPRP genotype, smoking and mutagen sensitivity.
Discussion
In the United States, lung cancer is most common among African-Americans and least prevalent among Mexican-Americans (9, 10) . Although these differences may be due to socioeconomic and lifestyle factors, underlying genetic factors may also contribute to this difference (14) . There is an expanding body of literature demonstrating that genetic polymorphisms, by modulating responses to carcinogenic exposure, play a role in cancer susceptibility and may partly explain ethnic differences in cancer incidence (15, 16) .
The association between the B allele of the PADPRP pseudogene on chromosome 13 and cancer susceptibility has been evaluated in several racial groups (7, 8, (17) (18) (19) . In a study of multiple myeloma and prostate cancer, Smulson (19) showed that the frequency of the B allele was strikingly greater than that of the A allele only in Black patients. In contrast, the frequency of the B allele did not differ among White patients with these diseases and a control group (7, 8, 18) . However, Doll et al. (17) found a significant association between prostate cancer and elevated A-allele frequencies. These studies all had small sample sizes. In our study, we showed a significant association between the B allele and lung cancer risk in Mexican-Americans. Furthermore, patients with the B allele were diagnosed with lung cancer at earlier ages and reported less tobacco smoking than individuals with the AA genotype (data not shown). This finding is similar to those reported for the susceptible cytochrome P4501A1 and p53 polymorphisms (14, 20, 21) and should be confirmed in a much larger study. Heavy exposure to the carcinogenic agents with which these genetic loci interact may mimic genetic effects (22) . Genetic differences in risk tend to be smaller at high doses of carcinogens when the effect of the carcinogen may overpower any genetic predisposition (20) . We found that the B-allele frequency was 0.598 in our African-American group but only 0.196 among the MexicanAmericans. Our data are in agreement with those from Doll et al. (17) , who reported a B-allele frequency of 0.56 in African-American controls. In our laboratory, we have also found that the B-allele frequency was 0.206 in Whites (data not shown). If the B allele is a susceptibility allele, its lower prevalence in Mexican-Americans may partly explain their lower rate of lung cancer. That the B allele frequency, which is greater in Mexican-American lung cancer patients than in Mexican-Americans without cancer, suggests that the B allele may be a valid marker for predisposition to lung cancer. However, although the frequency of the B allele was significantly higher in African-American controls than in MexicanAmerican controls, it is not clear why African-American lung cancer patients do not have higher B allele frequencies than African-Americans without lung cancer.
Lyn et al. (7) have suggested two possible mechanisms for how the chromosome 13 PADPRP pseudogene polymorphism may be linked to a predisposition to certain cancers. Although it is not known whether the chromosome 13 gene is expressed, the close sequence similarity between the A allele's deduced amino-acid sequence and the automodification domain of the active PADPRP protein suggests selection against amino-acid changes and could be an indication of functional similarity. The putative chromosome 13 protein might therefore compete with the active polymerase for ribosylation sites at DNA strand breaks. This mechanism was supported by our data. We found a significant association between the B allele and DNA breaks. The mean number of mutagen-induced breaks/cell was increased significantly in Mexican-American lung cancer patients as the number of copies of the B allele increased. The mean breaks/cell values were 1.1, 1.2 and 2.0 for patients with the AA, AB and BB genotypes respectively.
Another possible explanation for the PADPRP pseudogene's association with lung cancer is that the B allele may cosegregate with another gene whose function (or lack of function) contributes to the development of malignancy. The xeroderma pigmentosum complementation group G gene, previously known as ERCC5 and ERCM2, is located at 13q33-34 and so is of particular interest (23, 24) . As this gene is 97 involved in excision repair, it may play a role in carcinogenesis (25) .
We previously demonstrated that mutagen sensitivity was an independent risk factor for lung cancer (26) (27) (28) (29) (30) . The results of the study presented here suggest that there is a synergistic interaction between mutagen sensitivity and the PADPRP pseudogene susceptibility genotype in lung cancer risk. PADPRP has a major functional role in rejoining DNA strand breaks (31) . PADPRP activity is increased during repair of (Ϯ)-anti-benzo[a]pyrene diol epoxide-induced DNA damage in human peripheral blood lymphocytes (32) . Similarly, inhibition of PADPRP increases (Ϯ)-anti-benzo[a]pyrene diol epoxide-induced formation of micronuclei and p53 accumulation in isolated human peripheral blood lymphocytes (33). Satoh and Lindahl, and Ueda and Hayaishi (34, 35) have suggested that PADPRP binds tightly to DNA strand breaks; auto-poly(ADP-ribosyl)ation of the protein then affects its release and allows DNA repair enzymes to access damaged DNA lesions. If the putative chromosome 13 protein competes with the active polymerase for ribosylation sites at DNA strand breaks, the cellular DNA repair capacity will be interfered with. Increases in the level of unrepaired DNA adducts (e.g. due to reduced cellular repair capacity) may increase the frequency of chromosomal aberrations and thus mutations in critical genes.
In our study, stratified analysis suggested a possible geneenvironment interaction between the PADPRP susceptibility genotype and cigarette smoking in Mexican-Americans. The risk for lung cancer was dramatically increased in individuals who had both genetic defects and carcinogenic exposure. However, the interaction terms between PADPRP pseudogene genotypes and both cigarette smoking and mutagen sensitivity were not statistically significant in the logistic model. The lack of statistical significance might be due to the small numbers in the strata. A larger study is therefore warranted to confirm this finding.
There are some limitations to this study. Mexican-Americans constitute an admixed population; African-Americans are also an admixed population. Since the control group was a convenience sample from different sources, it is possible that they may vary in the degree of admixture and allele frequencies. Some controls were recruited from prostate cancer screening programs. It is possible that persons from cancer screening programs and other volunteers may be at higher risks for cancer, which would bias the ORs toward the null hypothesis.
In summary, we demonstrated that the B allele of the chromosome 13 PADPRP pseudogene can be used as a marker for lung carcinogenesis. Whether the chromosome 13 region that contains the PADPRP pseudogene harbors a gene whose loss predisposes individuals to malignancy, or that the PADPRP pseudogene itself has a functional role in DNA break rejoining, is not clear. More studies of the chromosome 13 PADPRP pseudogene and linked loci may help further our overall understanding of genetic predisposition to cancer.
